OncoMatch/Clinical Trials/NCT06838273
A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Is NCT06838273 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including BL-B01D1 and Osimertinib for non-small cell lung cancer.
Treatment: BL-B01D1 · Osimertinib · Osimertinib — This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with osimertinib versus osimertinib as first-Line treatment in patients with EGFR-mutated locally advanced or metastatic Non-small Cell Lung Cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR sensitive mutation
Documentation of EGFR sensitive mutations detected from tumor tissue or blood samples
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
Patients with previous systemic therapy
Cannot have received: EGFR tyrosine kinase inhibitor
Patients had received EGFR-TKI therapy
Cannot have received: autologous or allogeneic stem cell transplantation
Had autologous or allogeneic stem cell transplantation history
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
No severe cardiac dysfunction, left ventricular ejection fraction ≥50%
No severe cardiac dysfunction, left ventricular ejection fraction ≥50%; The organ function level must meet the requirements on the premise that blood transfusion and colony-stimulating factor are not allowed within 14 days before the screening period; Urinary protein ≤2+ or < 1000mg/24h
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify